Alzheimer’s research is advancing as new treatments, developed over decades, begin reaching patients. John Hardy, a leading researcher, emphasizes that scientific progress alone isn’t enough; better diagnosis and political support are crucial. Hardy’s work in the 1990s identified amyloid protein’s role in Alzheimer’s, leading to treatments like Donanemab and Lecanemab, which can remove amyloid deposits from the brain. While these drugs slow cognitive decline, they don’t stop the disease, extending its progression from about nine to twelve years. The amyloid theory remains debated, but most agree it plays a role. Hardy stresses the importance of improving diagnosis through genetics and biomarkers, similar to cholesterol tests for heart disease. In the UK, these drugs are available privately, while in the US, Lecanemab is FDA-approved.
QUESTION: How might advancements in Alzheimer’s treatment impact future healthcare policies and patient care?
The Next Alzheimer’s Breakthrough Will Take More Than Just Science
